In This Article:
Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types
Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing.
Stage 1 of the contract, launched in early 2024, focused on sourcing the required plants to develop a compound used to produce an approved drug product. Completion of Stage 1 indicates that the BioHarvest research team successfully isolated the cells of the target plant and mirrored, magnified and multiplied those cells in petri dishes using the Company's proprietary Botanical Synthesis platform.
Stage 2 involves the delivery of a sufficient amount of biomass to be tested for suitability and involves the development of optimal growing conditions in liquid media. Upon successful completion, the company would transfer to small and medium-scale production and ultimately enter production of commercial volumes of the target compound.
Ilan Sobel, Chief Executive Officer of BioHarvest Sciences, said: "This marks the first CDMO project to advance to Stage Two, and we are excited to continue working with a valued pharmaceutical partner on a high-impact therapeutic drug product. This milestone validates the versatility of our Botanical Synthesis platform to deliver scalable, cost-effective alternatives to traditional compound sourcing. Stage One success also reinforces our position as a trusted partner for pharma, nutrition, and nutraceutical players seeking next-generation plant-based solutions. We expect this achievement to accelerate additional CDMO opportunities as we help shape the future of therapeutics."
Dr. Zaki Rakib, Chairman and President of the CDMO Division, concluded: "Stage One carries the highest technical risk, requiring extensive AI-assisted research. Completing it successfully proves our platform can address a broad range of molecule families. Stage Two will focus on scaling biomass and refining compound concentration, and carries a much higher probability of success. Importantly, this project sharpened our analytical capabilities and validated our in-house AI tools, which will now support all future CDMO engagements."